Inventor · disambiguated record
Pekka Kallunki
Also filed as: KALLUNKI PEKKA
21 granted patents·8 pending applications·160 citations·filing 1994–2025
96Inventor score
Top patents by PatentIndex Score
29 records- 0198US11542323B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2020·Granted Jan 3, 2023·6 cites·24 claims
- 0298US11524995B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2020·Granted Dec 13, 2022·6 cites·20 claims
- 0397US11421024B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2020·Granted Aug 23, 2022·6 cites·23 claims
- 0497US10800836B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2016·Granted Oct 13, 2020·10 cites·10 claims
- 0597US10647764B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2019·Granted May 12, 2020·9 cites·14 claims
- 0697US10647763B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2019·Granted May 12, 2020·9 cites·14 claims
- 0797US10640554B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2019·Granted May 5, 2020·9 cites·14 claims
- 0896US10364285B2Antibodies for the treatment of synucleinopathyH LUNDBECK AS·Filed 2017·Granted Jul 30, 2019·13 cites·9 claims
- 0996US10358484B2Antibodies for the treatment of synucleinopathyH LUNDBECK AS·Filed 2017·Granted Jul 23, 2019·13 cites·9 claims
- 1096US10358483B2Antibodies for the treatment of synucleinopathyH LUNDBECK AS·Filed 2017·Granted Jul 23, 2019·13 cites·9 claims
- 1195US10358482B2Antibodies for the treatment of synucleinopathyH LUNDBECK AS·Filed 2017·Granted Jul 23, 2019·11 cites·9 claims
- 1294US12077578B2Compositions and methods for treating synucleinopathiesH LUNDBECK AS·Filed 2023·Granted Sep 3, 2024·5 cites·16 claims
- 1392US10889635B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2017·Granted Jan 12, 2021·6 cites·20 claims
- 1487US12358974B2Compositions and methods for treating synucleinopathiesH LUNDBECK AS·Filed 2024·Granted Jul 15, 2025·0 cites·33 claims
- 1587US12358975B2Compositions and methods for treating synucleinopathiesH LUNDBECK AS·Filed 2024·Granted Jul 15, 2025·0 cites·36 claims
- 1687US12351624B2Compositions and methods for treating synucleinopathiesH LUNDBECK AS·Filed 2024·Granted Jul 8, 2025·0 cites·34 claims
- 1785US2023312693A1Agents, Uses and Methods for the Treatment of SynucleinopathyH LUNDBECK AS·Filed 2022·Application pending·0 cites
- 1877US11325968B2Alpha-synuclein antibodiesH LUNDBECK AS·Filed 2017·Granted May 10, 2022·1 cites·9 claims
- 1977US6955924B2Laminin chains: diagnostic usesBIOSTRATUM INC·Filed 2001·Granted Oct 18, 2005·3 cites·6 claims
- 2076US5660982ALaminin chains: diagnostic usesFiled 1994·Granted Aug 26, 1997·31 cites·30 claims
- 2164US2005019332A1Laminin chains: diagnostic usesBIOSTRATUM INC·Filed 2004·Application pending·0 cites
- 2263US12421303B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2020·Granted Sep 23, 2025·0 cites·20 claims
- 2358US2007077252A1Laminin chains: diagnostic usesBIOSTRATUM INC·Filed 2006·Application pending·0 cites
- 2452US2005048518A1Laminin chains: diagnostic and therapeutic useFiled 2003·Application pending·0 cites
- 2550US2003100529A1Laminin chains: diagnostic and therapeutic useBIOSTRATUM AB·Filed 2002·Application pending·0 cites
- 2649US6143505ALaminin chains: diagnostic and therapeutic useFiled 1997·Granted Nov 7, 2000·9 cites·4 claims
- 2749US2025282855A1Compositions and methods for treating multiple system atrophy (msa)H LUNDBECK AS·Filed 2025·Application pending·0 cites
- 2848US2020309796A1Assay, method and treatment of alpha-synucleinopathiesH LUNDBECK AS·Filed 2018·Application pending·0 cites
- 2941US2004122216A1Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organsFiled 2003·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →